You don't think that being short 18% of your sales reps could lead to a 2% decline in sales (or treating 20 fewer patients during the quarter)? Wow are your negative opinions jaded.

You also completely ignore the potential for label expansion.

Explain how Tareceva a lung cancer drug is doing over $2 billion in sales today after flat or down periods earlier in its launch:

http://www.gene.com/gene/about/ir/historical/product-sales/tarceva.html

"First, let’s turn over in our sales force. Starting in 4Q 2011 Dendreon began to experience turnover in the sales force. This trend continued into 2012 and when we examined our result we found that those territories that experienced turnover were down 30% in quarter-over-quarter sales in Q2 versus those with the sales reps throughout the quarter. That said, we still have some territories open and we expect to stabilize the sales force in the third quarter. I’m pleased to report that we’ve not had any issues attracting top play sales talent."

"So, 18% of vacancies in June is the high number, that’s way higher than what we typically would see in the normal year in a normal quarter. So, we have seen that, I think we have seen it for a variety of reasons that I outlined earlier; one is past organizational changes that have occurred at Dendreon plus the other biotech companies preparing to launch going after your people that are experienced oncology sales force folks. The next component that you asked about is urology, and in urology clinics there is some key components to move into business for their, getting to urologist comfortable with using PROVENGE and immunotherapy in our process. The turnover certainly has affected urology practices and well as oncology practices."